Biocon Limited has commenced commercial sales of Yesafili (aflibercept-jbvf) in the United States, marking its entry into the high-value ophthalmology biosimilars market. The launch, effective August 3, 2026, targets a significant addressable market driven by an estimated 19.8 million Americans living with age-related macular degeneration (AMD). Yesafili serves as an interchangeable biosimilar to Regeneron’s reference product, Eylea 2 mg, allowing pharmacy-level substitution in accordance with state laws. This move strengthens Biocon’s presence in the US healthcare sector, leveraging its status as one of the first interchangeable biosimilars approved by the US Food and Drug Administration (FDA) in May 2024.

The company notified the Bombay Stock Exchange and the National Stock Exchange of India Limited regarding the launch pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was made in compliance with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. Rajesh U. Shanoy, Company Secretary and Compliance Officer, signed the intimation filed with the exchanges.

Yesafili is indicated for the treatment of several serious eye conditions, including neovascular (wet) AMD, macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy (DR). As a vascular endothelial growth factor (VEGF) inhibitor, it addresses a critical unmet need in a market where aflibercept sales totaled approximately $5.89 billion in 2023. The product’s approval was based on comprehensive analytical, nonclinical, and clinical data confirming its high similarity to Eylea 2 mg.

Shreehas Tambe, CEO & Managing Director of Biocon Ltd., stated that the launch represents a key step in expanding global availability of biosimilar Aflibercept 2 mg. He noted that the milestone builds on the company’s earlier FDA approval as one of the first interchangeable biosimilars to Eylea 2 mg, aiming to advance access to life-changing medicines for patients worldwide.

Clinical Validation and Safety

The approval for Yesafili relied on data from the Phase 3 INSIGHT Study, which compared the biosimilar against Eylea 2 mg in patients with Diabetic Macular Edema. The study demonstrated no clinically meaningful differences between the two products regarding pharmacokinetics, safety, efficacy, and immunogenicity. However, the product carries warnings for potential risks such as endophthalmitis, retinal detachments, and arterial thromboembolic events following intravitreal injections. Patients are advised to report any signs of infection or inflammation immediately.

What the Numbers Show

The commercialization of Yesafili positions Biocon to capture share in a mature but growing therapeutic area. With nearly 20 million Americans affected by AMD and a reference product generating nearly $6 billion in recent annual sales, the economic potential for biosimilar penetration is substantial. The interchangeable designation is a critical differentiator, as it permits automatic substitution at pharmacies without additional physician intervention, potentially accelerating adoption rates compared to non-interchangeable biosimilars. This regulatory advantage aligns with Biocon’s broader strategy of providing affordable alternatives in high-unmet-need therapy areas across chronic and non-communicable diseases.

Biocon Limited will announce its financial results for the first quarter of FY27 on Wednesday, August 05, 2026, following a scheduled meeting of its Board of Directors. The company will subsequently host an earnings conference call for analysts and investors on Thursday, August 06, 2026, at 10:00 hrs IST to discuss performance for the quarter ended June 30, 2026. This schedule ensures market participants have timely access to management commentary alongside the financial data.

The Board meeting, held pursuant to Regulation 29(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, will approve both standalone and consolidated un-audited results. Alongside these financial approvals, the Board will address other routine matters. The company has notified the Bombay Stock Exchange (BSE) and the National Stock Exchange of India Limited (NSE) regarding these proceedings.

In compliance with the Code of Conduct for Prevention of Insider Trading and the SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in Biocon’s securities has been closed. The blackout period commenced on Wednesday, July 01, 2026, and will remain in effect until Friday, August 07, 2026, inclusive. Trading will resume on Saturday, August 08, 2026.

The earnings conference call will be conducted over Zoom. Participants are advised to join ten minutes prior to the scheduled start time. Detailed registration information is available on the company’s investor relations website. Following the call, an audio recording will be accessible before the next trading day or within 24 hours, whichever is earlier. A video recording will be available within 48 hours.

Transcripts of the conference call will be published on the company’s website within five working days of its conclusion. All recordings and transcripts can be accessed under the Financial Information section of the Investor Relations page. For further inquiries, investors may contact Prashant Nair from the Investor Relations team.

Regulatory Disclosures

The intimation was signed by Rajesh U. Shanoy, Company Secretary and Compliance Officer, on July 28, 2026. The company includes a safe harbor statement noting that forward-looking statements made during the call involve risks and uncertainties. These include general economic conditions, R&D efforts, currency fluctuations, interest rate changes, and regulatory shifts in the biotechnology and pharmaceuticals sectors. Neither Biocon nor its directors assume an obligation to update these forward-looking statements.